Cefamandole: in vitro and clinical pharmacokinetics.
Cefamandole has a broader spectrum and greater potency than the other cephalosporins. It includes Haemophilus influenzae, most strains of Enterobacter, and many strains of indole-positive Proteus and Bacteroides, with a lower minimal inhibitory concentration for Escherichia coli, Klebsiella, etc. Concentrations of drug in the serum after the parenteral injection of cefamandole exceed manyfold the minimal inhibitory concentrations of over 82% of the bacteria studied. Approximately 65 to 85% is excreted in a biologically active form in the urine. This antibiotic offers advantages of antibacterial effectiveness and at the same time retains the safety of penicillin G and cephalothin in animals.
D000328:Adult; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D007700:Kinetics; D008297:Male; D008333:Mandelic Acids / Q000378:metabolism / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011485:Protein Binding; D013997:Time Factors
D002511:Cephalosporins; D008333:Mandelic Acids